Stéatose Hépatique Non-Alcoolique et Risque Cardiovasculaire chez le Diabétique Type 2 : Analyse d’une série de Patients d’un centre hospitalier universitaire

K BOUDAOUD; I CHEBEL; N NOURI

Authors

K BOUDAOUD Laboratory of Biology and Molecular Genetics, Constantine 3 University, Algeria
I CHEBEL Department of Endocrinology Diabetology, CHU Benbadis Constantine, Algeria
N NOURI Faculty of Medicine, Constantine 3 University. Algeria

Keywords:

Non-alcoholic fatty liver disease, Cardiovascular risk, Type 2 diabetes, NAFLD fibrosis score, Fibrosis-4 score

Abstract

AIM= Cardiovascular risk assessment(CVR) in type 2 diabetic (MDT2) patients with Non-alcoholic fatty liver disease(NAFLD)

Patients and methods Retrospective study of 89 T2DM with ultrasound hepatic steatosis. The CVR assessed according to the ESC 2021 guidelines. The risk of fibrosis is assessed by the NAFLD fibrosis score (NFS). Fibrosis was assessed using the fibrosis-4 score(Fib-4).

Results. NAFLD found in 23% of patients without NASH, aged 52±8 years, diabetic for 13.55±7 years, sex ratio F:H 1.5. The CVR is very high in 80%, moderate in 20% of patients. We note 55% of obese patients, 70% of dyslipidemic patients and 20% of cases of hepatic cytolysis. NFS indicates fibrosis in 25% and remains indeterminate in 30% of cases.

Discuss. NAFLD is often associated with insulin resistance and strongly associated with DMT2 and a higher risk of CVD. In addition to being at risk of advanced fibrosis and cirrhosis, NAFLD patients are also at higher risk of cardiovascular disease which is consistent with our results. Close monitoring of diabetics with NAFLD is recommended to prevent major vascular events. Risk stratification scores are needed that address both the risk for advanced liver disease and CVD.

Downloads

Download data is not yet available.

References

SM. Francque, G Marchesini, A Kautz et al. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep. 2021 Oct; 3(5): 100322. Disponible sur https://pubmed.ncbi.nlm.nih.gov/34693236/

La maladie du foie gras non-alcoolique (NAFLD), Disponible sur https://www.chudequebec.ca/getmedia/219e90f1-827c-4295-8409-6e8d8e5bad5f/823_14_063_NAFLD_NASH.aspx

Muzica CM, Sfarti C, Trifan A, et al. Nonalcoholic fatty liver disease and type 2 diabetes mellitus: a bidirectional relationship. Can J Gastroenterol Hepatol 2020; 2020: 6638306. Disponible sur https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781697/

AP Delli Bovi, F Marciano, C Mandato et al. Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. Front Med (Lausanne). 2021; 8: 595371. Disponible sur https://www.frontiersin.org/articles/10.3389/fmed.2021.595371/full

FLJ Visseren, F Mach, YM Smulders et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-3337. Disponible sur https://pubmed.ncbi.nlm.nih.gov/34458905/

The NASH education program. Disponible sur www.the-nash-education-program.com

N Motamed, H Ajdarkosh, Ml Ahmadi et al. Non-alcoholic fatty liver disease is not independent risk factor for cardiovascular disease event: A cohort study. World J Hepatol. 2020 Jun 27; 12(6): 323–331. Disponible sur https://pubmed.ncbi.nlm.nih.gov/32742574/

Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in non-alcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008;48:792-8. Disponible sur https://pubmed.ncbi.nlm.nih.gov/18752331/

EASL. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388-402. Disponible sur https://pubmed.ncbi.nlm.nih.gov/27062661/

Xiao H, Shi M, Xie Y, et al. Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis. PLoS One 2017 Nov 6;12(11):e0186660. Disponible sur https://pubmed.ncbi.nlm.nih.gov/29107943/